Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of trifluridine for recurrence of colorectal liver metastasis
jRCT1031220052Phase 2Recruiting
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine in colorectal cancer (CRC). Primary endpoint: Progression-free survival at 2 years. Started Jul 2022; status: recruiting.
02
Drugs
trifluridine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT1031220052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031220052.